Abstract
BackgroundVascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGF TKIs) and immune checkpoint inhibitors (ICIs) have been shown to be effective and safe in the treatment of metastatic renal cell carcinoma. Thus, the use of these agents is being evaluated in the adjuvant therapeutic setting following surgical resection.ObjectiveThis article provides a review of positive and negative results from clinical trials assessing the adjuvant treatment of renal cell carcinoma.Materials and methodsFor the review, relevant phase III studies as well as recent conference abstracts (American Society of Clinical Oncology [ASCO], European Society of Medical Oncology [ESMO]) and current guidelines (European Association of Urology [EAU]) were summarized, considering clinical relevance, and providing a critical interpretation.Results and conclusionCurrently, adjuvant therapy with the PD‑1 inhibitor pembrolizumab is recommended for 1 year in patients with high-risk renal cell carcinoma (defined by KEYNOTE-564). Other checkpoint inhibitors (atezolizumab, nivolumab+ipilimumab, nivolumab) as well as VEGF TKIs are accompanied by high toxicity and show no advantage in the adjuvant therapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
